Biomarkers of Cardiovascular Damage and Dysfunction-An Overview

Heart Lung and Circulation

Volumn 16, Issue SUPPL. 3, 2007, Pages

  Collinson, Paul O ^a   Gaze, David C ^a  

^a ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

Acute coronary syndrome; B type natriuretic peptide; Biomarkers; Cardiac troponin I; Cardiac troponin T; Chest pain; Ischaemia; Ischaemia modified albumin; Myocardial infarction; N terminal B type natriuretic peptide; Prognostic risk assessment; Troponin

Indexed keywords

ACETYLSALICYLIC ACID; ALBUMIN; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CHOLINE; CREATINE KINASE MB; FATTY ACID; FIBRINOGEN RECEPTOR ANTAGONIST; LOW MOLECULAR WEIGHT HEPARIN; NATRIURETIC PEPTIDE TYPE C; TROPONIN I; TROPONIN T;

ACUTE CORONARY SYNDROME; ACUTE HEART FAILURE; ACUTE HEART INFARCTION; AREA UNDER THE CURVE; ARTICLE; ATHEROSCLEROTIC PLAQUE; BLOOD CLOT LYSIS; CARDIOVASCULAR DISEASE; CELL DEATH; COLLATERAL CIRCULATION; DIAGNOSTIC VALUE; DISEASE COURSE; HEART FAILURE; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HUMAN; MEDICAL ASSESSMENT; PATHOLOGICAL ANATOMY; PATHOPHYSIOLOGY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; REFERENCE VALUE; RUPTURE; SENSITIVITY AND SPECIFICITY; ST SEGMENT ELEVATION;

ACUTE CORONARY SYNDROME; ACUTE DISEASE; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CHEST PAIN; HUMANS; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROGNOSIS; RISK ASSESSMENT; TROPONIN I; TROPONIN T;

EID: 34547738926     PISSN: 14439506     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hlc.2007.05.006     Document Type: Article

References (73)

1. Davies M.J. Stability and instability: two faces of coronary atherosclerosis. The Paul Dudley White lecture 1995. Circulation 94 (1996) 2013-2020
2. Hong M.K., Mintz G.S., Lee C.W., Kim Y.H., Lee S.W., Song J.M., Han K.H., Kang D.H., Song J.K., Kim J.J., Park S.W., and Park S.J. Comparison of coronary plaque rupture between stable angina and acute myocardial infarction: a three-vessel intravascular ultrasound study in 235 patients. Circulation 110 (2004) 928-933
3. Davies M.J., Thomas A.C., Knapman P.A., and Hangartner J.R. Intramyocardial platelet aggregation in patients with unstable angina suffering sudden ischemic cardiac death. Circulation 73 (1986) 418-427
4. Apple F.S., Wu A.H., Mair J., Ravkilde J., Panteghini M., Tate J., Pagani F., Christenson R.H., Mockel M., Danne O., and Jaffe A.S. Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome. Clin Chem 51 (2005) 810-824
5. Collinson P. Of bombers, radiologists, and cardiologists: time to ROC. Heart 80 (1998) 215-217
6. Danne O., Mockel M., Lueders C., Mugge C., Zschunke G.A., Lufft H., Muller C., and Frei U. Prognostic implications of elevated whole blood choline levels in acute coronary syndromes. Am J Cardiol 91 (2003) 1060-1067
7. Kleinfeld A.M., Prothro D., Brown D.L., Davis R.C., Richieri G.V., and DeMaria A. Increases in serum unbound free fatty acid levels following coronary angioplasty. Am J Cardiol 78 (1996) 1350-1354
8. Aguirre F.V., Younis L.T., Chaitman B.R., Ross A.M., McMahon R.P., Kern M.J., Berger P.B., Sopko G., Rogers W.J., and Shaw L. Early and 1-year clinical outcome of patients' evolving non-Q-wave versus Q-wave myocardial infarction after thrombolysis. Results from The TIMI II study. Circulation 91 (1995) 2541-2548
9. Chan B., Dodsworth N., Woodrow J., Tucker A., and Harris R. Site-specific N-terminal auto-degradation of human serum albumin. Eur J Biochem 227 (1995) 524-528
10. Bar-Or D., Winkler J.V., Vanbenthuysen K., Harris L., Lau E., and Hetzel F.W. Reduced albumin-cobalt binding with transient myocardial ischemia after elective percutaneous transluminal coronary angioplasty: a preliminary comparison to creatine kinase-MB, myoglobin, and troponin I. Am Heart J 141 (2001) 985-991
11. Bhagavan N.V., Lai E.M., Rios P.A., Yang J., Ortega-Lopez A.M., Shinoda H., Honda S.A., Rios C.N., Sugiyama C.E., and Ha C.E. Evaluation of human serum albumin cobalt binding assay for the assessment of myocardial ischemia and myocardial infarction. Clin Chem 49 (2003) 581-585
12. Wu A.H., Morris D.L., Fletcher D.R., Apple F.S., Christenson R.H., and Painter P.C. Analysis of the albumin cobalt binding (ACB) test as an adjunct to cardiac troponin I for the early detection of acute myocardial infarction. Cardiovasc Toxicol 1 (2001) 147-151
13. Christenson R.H., Duh S.H., Sanhai W.R., Wu A.H., Holtman V., Painter P., Branham E., Apple F.S., Murakami M., and Morris D.L. Characteristics of an albumin cobalt binding test for assessment of acute coronary syndrome patients: a multicenter study. Clin Chem 47 (2001) 464-470
14. Sinha M.K., Roy D., Gaze D.C., Collinson P.O., and Kaski J.C. Role of "Ischemia Modified Albumin", a new biochemical marker of myocardial ischaemia, in the early diagnosis of acute coronary syndromes. Emerg Med J 21 (2004) 29-34
15. Collinson P.O., Gaze D.C., Bainbridge K., Morris F., Morris B., Price A., and Goodacre S. Utility of admission cardiac troponin and "Ischemia Modified Albumin" measurements for rapid evaluation and rule out of suspected acute myocardial infarction in the emergency department. Emerg Med J 23 (2006) 256-261
16. Peacock F., Morris D.L., Anwaruddin S., Christenson R.H., Collinson P.O., Goodacre S.W., Januzzi J.L., Jesse R.L., Kaski J.C., Kontos M.C., Lefevre G., Mutrie D., Sinha M.K., Uettwiller-Geiger D., and Pollack C.V. Meta-analysis of ischemia-modified albumin to rule out acute coronary syndromes in the emergency department. Am Heart J 152 (2006) 253-262
17. Myocardial infarction redefined-a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. Eur Heart J 2000; 21 1502-1513.
18. Collinson P.O., Boa F.G., and Gaze D.C. Measurement of cardiac troponins. Ann Clin Biochem 38 (2001) 423-449
19. Collinson P.O., Stubbs P.J., and Kessler A.C. Multicentre evaluation of the diagnostic value of cardiac troponin T, CK-MB mass, and myoglobin for assessing patients with suspected acute coronary syndromes in routine clinical practice. Heart 89 (2003) 280-286
20. Fredericks S., Murray J.F., Bewick M., Chang R., Collinson P.O., Carter N.D., and Holt D.W. Cardiac troponin T and creatine kinase MB are not increased in exterior oblique muscle of patients with renal failure. Clin Chem 47 (2001) 1023-1030
21. Fredericks S., Bainbridge K., Murray J.F., Collinson P.O., Carter N.D., and Holt D.W. Measurement of cardiac troponin I in striated muscle using three experimental methods. Ann Clin Biochem 40 (2003) 244-248
22. Fleming S.M., and Daly K.M. Cardiac troponins in suspected acute coronary syndrome: a meta-analysis of published trials. Cardiology 95 (2001) 66-73
23. Heidenreich P.A., Alloggiamento T., Melsop K., McDonald K.M., Go A.S., and Hlatky M.A. The prognostic value of troponin in patients with non-ST elevation acute coronary syndromes: a meta-analysis. J Am Coll Cardiol 38 (2001) 478-485
24. Labugger R., Organ L., Collier C., Atar D., and Van Eyk J.E. Extensive troponin I and T modification detected in serum from patients with acute myocardial infarction. Circulation 102 (2000) 1221-1226
25. McDonough J.L., Labugger R., Pickett W., Tse M.Y., MacKenzie S., Pang S.C., Atar D., Ropchan G., and Van Eyk J.E. Cardiac troponin I is modified in the myocardium of bypass patients. Circulation 103 (2001) 58-64
26. Stubbs P., Collinson P., Moseley D., Greenwood T., and Noble M. Prognostic significance of admission troponin T concentrations in patients with myocardial infarction. Circulation 94 (1996) 1291-1297
27. Rao A.C., Collinson P.O., Rose A.J., John C., Canepa-Anson R., and Joseph S.P. Prospective evaluation of the role of routine cardiac troponin T measurement to identify left ventricular ejection fraction <40% after first myocardial infarction. Heart 89 (2003) 559-560
28. Panteghini M., Cuccia C., Bonetti G., Giubbini R., Pagani F., and Bonini E. Single-point cardiac troponin T at coronary care unit discharge after myocardial infarction correlates with infarct size and ejection fraction. Clin Chem 48 (2002) 1432-1436
29. Lindahl B., Andren B., Ohlsson J., Venge P., Wallentin L., and Frisk Study Group. Risk stratification in unstable coronary artery disease. Additive value of troponin T determinations and pre-discharge exercise tests. Eur Heart J 18 (1997) 762-770 [see comments]
30. Kontos M.C. Evaluation of the emergency department chest pain patient. Cardiol Rev 9 (2001) 266-275
31. Lindahl B., Venge P., Wallentin L., and Fragmin in Unstable Coronary Artery Disease (FRISC) Study Group. Troponin T identifies patients with unstable coronary artery disease who benefit from long-term antithrombotic protection. J Am Coll Cardiol 29 (1997) 43-48
32. Boersma E., Harrington R.A., Moliterno D.J., White H., Theroux P., Van de W.F., de Torbal A., Armstrong P.W., Wallentin L.C., Wilcox R.G., Simes J., Califf R.M., Topol E.J., and Simoons M.L. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet 359 (2002) 189-198
33. Cannon C.P., Weintraub W.S., Demopoulos L.A., Vicari R., Frey M.J., Lakkis N., Neumann F.J., Robertson D.H., DeLucca P.T., DiBattiste P.M., Gibson C.M., and Braunwald E. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 344 (2001) 1879-1887
34. Bertrand M.E., Simoons M.L., Fox K.A., Wallentin L.C., Hamm C.W., McFadden E., de Feyter P.J., Specchia G., and Ruzyllo W. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 23 (2002) 1809-1840
35. Goodacre S., Nicholl J., Dixon S., Cross E., Angelini K., Arnold J., Revill S., Locker T., Capewell S.J., Quinney D., Campbell S., and Morris F. Randomised controlled trial and economic evaluation of a chest pain observation unit compared with routine care. BMJ 328 (2004) 254-260
36. Collinson P.O., Gaze D.C., Morris F., Morris B., Price A., and Goodacre S. Comparison of biomarker strategies for rapid rule out of myocardial infarction in the emergency department using ACC/ESC diagnostic criteria. Ann Clin Biochem 43 (2006) 273-280
37. Bhayana V., Gougoulias T., Cohoe S., and Henderson A.R. Discordance between results for serum troponin T and troponin I in renal disease. Clin Chem 41 (1995) 312-317 [see comments]
38. Collinson P.O., Hadcocks L., Foo Y., Rosalki S.B., Stubbs P.J., Morgan S.H., and O'Donnell J. Cardiac troponins in patients with renal dysfunction. Ann Clin Biochem 35 Pt 3 (1998) 380-386
39. Apple F.S., Murakami M.M., Pearce L.A., and Herzog C.A. Predictive value of cardiac troponin I and T for subsequent death in end-stage renal disease. Circulation 106 (2002) 2941-2945
40. Khan N.A., Hemmelgarn B.R., Tonelli M., Thompson C.R., and Levin A. Prognostic value of troponin T and I among asymptomatic patients with end-stage renal disease: a meta-analysis. Circulation 112 (2005) 3088-3096
41. Sharma R., Gaze D.C., Pellerin D., Metha R., Gregson H., Streather C.P., Collinson P.O., and Brecker S.J. Cardiac structural and functional abnormalities in end stage renal disease patients with elevated cardiac troponin T. Heart (2005)
42. Herrmann J. Peri-procedural myocardial injury: 2005 update. Eur Heart J 26 (2005) 2493-2519
43. Ricciardi M.J., Wu E., Davidson C.J., Choi K.M., Klocke F.J., Bonow R.O., Judd R.M., and Kim R.J. Visualization of discrete microinfarction after percutaneous coronary intervention associated with mild creatine kinase-MB elevation. Circulation 103 (2001) 2780-2783
44. Selvanayagam J.B., Porto I., Channon K., Petersen S.E., Francis J.M., Neubauer S., and Banning A.P. Troponin elevation after percutaneous coronary intervention directly represents the extent of irreversible myocardial injury: insights from cardiovascular magnetic resonance imaging. Circulation 111 (2005) 1027-1032
45. Cutlip D.E., and Kuntz R.E. Does creatinine kinase-MB elevation after percutaneous coronary intervention predict outcomes in 2005? Cardiac enzyme elevation after successful percutaneous coronary intervention is not an independent predictor of adverse outcomes. Circulation 112 (2005) 916-922
46. Bhatt D.L., and Topol E.J. Does creatinine kinase-MB elevation after percutaneous coronary intervention predict outcomes in 2005? Periprocedural cardiac enzyme elevation predicts adverse outcomes. Circulation 112 (2005) 906-915
47. Ioannidis J.P., Karvouni E., and Katritsis D.G. Mortality risk conferred by small elevations of creatine kinase-MB isoenzyme after percutaneous coronary intervention. J Am Coll Cardiol 42 (2003) 1406-1411
48. Akkerhuis K.M., Alexander J.H., Tardiff B.E., Boersma E., Harrington R.A., Lincoff A.M., and Simoons M.L. Minor myocardial damage and prognosis: are spontaneous and percutaneous coronary intervention-related events different?. Circulation 105 (2002) 554-556
49. Cavallini C., Savonitto S., Violini R., Arraiz G., Plebani M., Olivari Z., Rubartelli P., Battaglia S., Niccoli L., Steffenino G., and Ardissino D. Impact of the elevation of biochemical markers of myocardial damage on long-term mortality after percutaneous coronary intervention: results of the CK-MB and PCI study. Eur Heart J 26 (2005) 1494-1498
50. Miller W.L., Garratt K.N., Burritt M.F., Lennon R.J., Reeder G.S., and Jaffe A.S. Baseline troponin level: key to understanding the importance of post-PCI troponin elevations. Eur Heart J 27 (2006) 1061-1069
51. Collinson P.O., and Stubbs P.J. Are troponins confusing?. Heart 89 (2003) 1285-1287
52. Giuliani I., Rieunier F., Larue C., Delagneau J.F., Granier C., Pau B., Ferriere M., Saussine M., Cristol J.P., Dupuy A.M., Merigeon E., Merle D., and Villard S. Assay for measurement of intact B-type natriuretic peptide prohormone in blood. Clin Chem 52 (2006) 1054-1061
53. Hawkridge A.M., Heublein D.M., Bergen III H.R., Cataliotti A., Burnett Jr. J.C., and Muddiman D.C. Quantitative mass spectral evidence for the absence of circulating brain natriuretic peptide (BNP-32) in severe human heart failure. Proc Natl Acad Sci USA 102 (2005) 17442-17447
54. Seferian K.R., Tamm N.N., Semenov A.G., Mukharyamova K.S., Tolstaya A.A., Koshkina E.V., Kara A.N., Krasnoselsky M.I., Apple F.S., Esakova T.V., Filatov V.L., and Katrukha A.G. The brain natriuretic peptide (BNP) precursor is the major immunoreactive form of bnp in patients with heart failure. Clin Chem 53 (2007) 866-873
55. Hunt P.J., Richards A.M., Nicholls M.G., Yandle T.G., Doughty R.N., and Espiner E.A. Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-PROBNP): a new marker of cardiac impairment. Clin Endocrinol (Oxf) 47 (1997) 287-296
56. Barnes S.C., Collinson P.O., Galasko G., Lahiri A., and Senior R. Evaluation of N-terminal pro-B type natriuretic peptide analysis on the Elecsys 1010 and 2010 analysers. Ann Clin Biochem 41 (2004) 459-463
57. Cowie M.R., and Zaphiriou A. Management of chronic heart failure. BMJ 325 (2002) 422-425
58. Galasko G.I., Lahiri A., Barnes S.C., Collinson P., and Senior R. What is the normal range for N-terminal pro-brain natriuretic peptide? How well does this normal range screen for cardiovascular disease?. Eur Heart J 26 (2005) 2269-2276
59. Groenning B.A., Raymond I., Hildebrandt P.R., Nilsson J.C., Baumann M., and Pedersen F. Diagnostic and prognostic evaluation of left ventricular systolic heart failure by plasma N-terminal pro-brain natriuretic peptide concentrations in a large sample of the general population. Heart 90 (2004) 297-303
60. Richards A.M., Doughty R., Nicholls M.G., Macmahon S., Ikram H., Sharpe N., Espiner E.A., Frampton C., Yandle T.G., and Australia-New Zealand Heart Failure Group. Neurohumoral prediction of benefit from carvedilol in ischemic left ventricular dysfunction. Circulation 99 (1999) 786-792
61. Anand I.S., Fisher L.D., Chiang Y.T., Latini R., Masson S., Maggioni A.P., Glazer R.D., Tognoni G., and Cohn J.N. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 107 (2003) 1278-1283
62. Latini R., Masson S., Anand I., Judd D., Maggioni A.P., Chiang Y.T., Bevilacqua M., Salio M., Cardano P., Dunselman P.H., Holwerda N.J., Tognoni G., and Cohn J.N. Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT). Circulation 106 (2002) 2454-2458
63. Masson S., Latini R., Anand I.S., Vago T., Angelici L., Barlera S., Missov E.D., Clerico A., Tognoni G., and Cohn J.N. Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) data. Clin Chem 52 (2006) 1528-1538
64. Troughton R.W., Frampton C.M., Yandle T.G., Espiner E.A., Nicholls M.G., and Richards A.M. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 355 (2000) 1126-1130
65. Maisel A.S., Krishnaswamy P., Nowak R.M., McCord J., Hollander J.E., Duc P., Omland T., Storrow A.B., Abraham W.T., Wu A.H., Clopton P., Steg P.G., Westheim A., Knudsen C.W., Perez A., Kazanegra R., Herrmann H.C., and McCullough P.A. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 347 (2002) 161-167
66. Januzzi J.L., van Kimmenade R., Lainchbury J., Bayes-Genis A., Ordonez-Llanos J., Santalo-Bel M., Pinto Y.M., and Richards M. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. Eur Heart J 27 (2006) 330-337
67. Mueller C., Scholer A., Laule-Kilian K., Martina B., Schindler C., Buser P., Pfisterer M., and Perruchoud A.P. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med 350 (2004) 647-654
68. de Lemos J.A., Morrow D.A., Bentley J.H., Omland T., Sabatine M.S., McCabe C.H., Hall C., Cannon C.P., and Braunwald E. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 345 (2001) 1014-1021
69. Jernberg T., Stridsberg M., Venge P., and Lindahl B. N-terminal pro brain natriuretic peptide on admission for early risk stratification of patients with chest pain and no ST-segment elevation PG. J Am Coll Cardiol 40 (2002) 437-445
70. Richards A.M., Nicholls M.G., Espiner E.A., Lainchbury J.G., Troughton R.W., Elliott J., Frampton C., Turner J., Crozier I.G., and Yandle T.G. B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction. Circulation 107 (2003) 2786-2792
71. Sabatine M.S., Morrow D.A., de Lemos J.A., Gibson C.M., Murphy S.A., Rifai N., McCabe C., Antman E.M., Cannon C.P., and Braunwald E. Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation 105 (2002) 1760-1763
72. James S.K., Lindahl B., Siegbahn A., Stridsberg M., Venge P., Armstrong P., Barnathan E.S., Califf R., Topol E.J., Simoons M.L., and Wallentin L. N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies To Open occluded arteries (GUSTO)-IV substudy. Circulation 108 (2003) 275-281
73. Kragelund C., Gronning B., Kober L., Hildebrandt P., and Steffensen R. N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Engl J Med 352 (2005) 666-675